Biogen, Ontogeny deal

The companies agreed to discover and develop three Hedgehog cell differentiation proteins, with an initial focus on central nervous system disorders including Parkinson's disease and amyotrophic lateral sclerosis. If all three product candidates are commercialized, Ontogeny could receive up to $80 million in license fees and milestones. BGEN will provide $6 million in research funding over the next two years, and will pay licensing fees and milestones of up to $27 million for each of the three potential products. ...